2012
Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
Lazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM. Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome. Clinical Cancer Research 2012, 18: 370-379. PMID: 22080440, PMCID: PMC4825867, DOI: 10.1158/1078-0432.ccr-11-1282.Peer-Reviewed Original ResearchConceptsMelanoma tissue microarrayTissue microarrayBreast cancerLC3B expressionClinical outcomesNuclear gradeKi-67Solid tumorsHigh LC3B expressionHigh nuclear gradeMultitumor tissue microarrayTypes of cancerHigh LC3BCutaneous metastasesPoor outcomeWorse outcomesHistopathologic gradingLC3B stainingTherapeutic vulnerabilitiesTumorsCancerCancer progressionMetastasisMitotic figuresLC3B levels
2005
Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer
Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer. Clinical Cancer Research 2005, 11: 8637-8643. PMID: 16361548, DOI: 10.1158/1078-0432.ccr-05-1436.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorOvarian cancerOverall survivalPrognostic valuePlatinum-paclitaxel combination chemotherapyAdvanced stage ovarian cancerDisease-free survivalSignificant prognostic factorsAdverse prognostic indicatorEpithelial ovarian cancerTumor EGFR expressionEGFR expression statusImportant prognostic informationConflicting resultsEpidermal growth factor receptor expression levelsEGFR protein expressionReceptor expression levelsGrowth factor receptorSurgical debulkingCombination chemotherapyPrognostic factorsMultivariable analysisEntire cohortPoor outcomePrognostic indicator
2001
β-Catenin Dysregulation in Thyroid Neoplasms Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis
Garcia-Rostan G, Camp R, Herrero A, Carcangiu M, Rimm D, Tallini G. β-Catenin Dysregulation in Thyroid Neoplasms Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis. American Journal Of Pathology 2001, 158: 987-996. PMID: 11238046, PMCID: PMC1850336, DOI: 10.1016/s0002-9440(10)64045-x.Peer-Reviewed Original ResearchMeSH KeywordsAdenomaAdultAgedBeta CateninBiomarkers, TumorCarcinomaCell DivisionCell NucleusCytoskeletal ProteinsDown-RegulationExonsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedOncogene Protein p21(ras)PhenotypePoint MutationPolymorphism, Single-Stranded ConformationalPrognosisSurvival RateThyroid NeoplasmsTrans-ActivatorsConceptsPoor prognosisTumor differentiationBeta-catenin expressionConventional prognostic indicatorsAggressive tumor phenotypeNuclear beta-catenin localizationThyroid tumor samplesBeta-catenin dysregulationAberrant nuclear expressionΒ-catenin dysregulationDifferentiated tumorsPrognostic indicatorThyroid cancerThyroid neoplasmsNuclear immunoreactivityBeta-catenin alterationsNuclear expressionTumor samplesProgressive lossCarcinomaTumor phenotypeSingle-strand conformational polymorphismBeta-catenin mutationsHuman cancersDown regulation
1999
Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma
Camp R, Rimm E, Rimm D. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86: 2259-2265. PMID: 10590366, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2259::aid-cncr13>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsAxillary lymph node negative breast carcinomaLymph node negative breast carcinomaExpression of METNode-negative breast carcinomaNegative breast carcinomaBreast carcinomaMET expressionMetastatic diseaseRelative riskNegative invasive ductal carcinomaLow Met expressionMET-negative patientsIndependent predictive valueIndependent prognostic markerUseful prognostic indicatorInvasive ductal carcinomaStandard immunoperoxidase techniqueHigh MET expressionHepatocyte growth factorActivation of METAxillary lymphNegative patientsPatient agePrognostic factorsAggressive disease